Innovation Pharma obtains FDA guidance for Brilacidin Phase 3 program
Category: #health  By Mateen Dalal  Date: 2019-05-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Innovation Pharma obtains FDA guidance for Brilacidin Phase 3 program

Brilacidin oral rinse is supposedly being developed as part of FDA Fast Track designation for Oral Mucositis

Reports confirm that Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, has recently received End-of-Phase 2 meeting minutes from the US Food and Drug Administration (FDA), which would help to guide the planned Phase 3 program of the company for Brilacidin oral rinse.

Apparently, the program is aimed at studying Brilacidin to reduce the incidence of Severe Oral Mucositis or SOM in neck and head cancer patients undergoing chemoradiation.

Brilacidin oral rinse is supposedly being developed as part of FDA’s Fast Track designation for Oral Mucositis. In December 2018, when the EoP2 meeting was summoned, FDA and Innovation Pharmaceuticals agreed to a suitable Phase 3 development pathway of Brilacidin.

FDA’s guidance now also aids to frame continuing discussions with the European Medicines Agency under the Scientific Advice process. The purpose of both these interactions is to safeguard proposed plans which meet regulatory needs for New Drug Application or Marketing Authorization Application filings, and eventually to get Brilacidin approved for Severe Oral Mucositis in HNC in both Europe and the United States.

According to President and Chief Medical Officer of Innovation Pharmaceuticals, Arthur P. Bertolino, MD, PhD, MBA, Brilacidin oral rinse helps in reducing the incidence of SOM which signifies a potential future regimen for millions of neck and head cancer patients, where currently no approved drug exists.

Dr. Bertolino added that moreover, the company hopes that Brilacidin will ultimately develop as a treatment for other indications where SOM is also considered as a recurrent side-effect of cancer therapies.

Chief Executive Officer of Innovation Pharmaceuticals, Leo Ehrlich, said that treatment associated with SOM in cancer patients is an actual problem globally, which affects millions of patients with financial and physical ramifications.

Ehrlich mentioned that presently, Innovation Pharmaceuticals is the only company advancing into late-stage trials with an oral drug candidate and positioned to meet this unmet requirement. The company is looking forward to initiating the planned Phase 3 program that adds value and credibility to the Brilacidin Franchise.

 

Source Credit: https://www.globenewswire.com/news-release/2019/05/01/1813598/0/en/Innovation-Pharmaceuticals-Receives-FDA-End-of-Phase-2-Meeting-Minutes.html

http://www.ipharminc.com/press-release/2019/5/1/innovation-pharmaceuticals-receives-fda-end-of-phase-2-meeting-minutes

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...